What is Marrone Bio Innovations Financial Strength?
Marrone Bio Innovations has the Financial Strength Rank of 2. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.
Warning Sign:
Marrone Bio Innovations Inc displays poor financial strength. Usually, this is caused by too much debt for the company.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Marrone Bio Innovations did not have earnings to cover the interest expense.
Marrone Bio Innovations's debt to revenue ratio for the quarter that ended in Mar. 2022 was 0.80.
As of today, Marrone Bio Innovations's Altman Z-Score is -5.45.
Competitive Comparison of Marrone Bio Innovations's Financial Strength
For the Agricultural Inputs subindustry, Marrone Bio Innovations's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marrone Bio Innovations's Financial Strength Distribution in the Agriculture Industry
For the Agriculture industry and Basic Materials sector, Marrone Bio Innovations's Financial Strength distribution charts can be found below:
* The bar in red indicates where Marrone Bio Innovations's Financial Strength falls into.
Marrone Bio Innovations Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Marrone Bio Innovations's Interest Expense for the
months ended in Mar. 2022 was $-0.55 Mil. Its Operating Income for the
months ended in Mar. 2022 was $-7.02 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2022 was $9.75 Mil.
Marrone Bio Innovations's Interest Coverage for the quarter that ended in Mar. 2022 is
| Marrone Bio Innovations did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Marrone Bio Innovations's Debt to Revenue Ratio for the quarter that ended in Mar. 2022 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Marrone Bio Innovations has a Z-score of -5.45, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
Warning Sign:
Altman Z-score of -5.45 is in distress zone. This implies bankruptcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Marrone Bio Innovations (Marrone Bio Innovations) Business Description
Traded in Other Exchanges
N/A
Address
7780-420 Brier Creek Parkway,, Raleigh, NC, USA, 27617
Marrone Bio Innovations Inc is a US-based agricultural company engaged in the discovery, development and sale of innovative biological products for crop protection, crop health and crop nutrition. The company produces bio-based pest management and plant health products such as Biopesticides, Bioinsecticides, Bionematicides, Biofungicides, Biostimulants and Bionutrition, among others. It generates key revenue from the sales of Marrone products, mainly Regalia, Grandevo and Venerate.
Executives
| Pamela G Marrone |
director, officer: CEO and President |
C/O MARRONE BIO INNOVATIONS, INC., 2121 SECOND STREET, A-107, DAVIS CA 95618 |
| Ladon Johnson |
officer: Interim CFO |
C/O MARRONE BIO INNOVATIONS, INC. 7780-420 BRIER CREEK PARWAY RALEIGH NC 27617-7882 |
| Ardsley Ridgecrest Partners Fund, L.p. |
other: See Footnote (1) |
262 HARBOR DRIVE, 4TH FLOOR, STAMFORD CT 06902 |
| Suping (sue) Cheung |
officer: Chief Financial Officer |
C/O QUICKLOGIC CORPORATION, SUNNYVALE CA 94089 |
| Matti Tiainen |
officer: SVP, International Sales |
C/O MARRONE BIO INNOVATIONS, INC. 1540 DREW AVENUE DAVIS CA 95618 |
| Lara L Lee |
director |
C/O MARRONE BIO INNOVATIONS, INC., 1540 DREW AVENUE, DAVIS CA 95618 |
| Kevin Helash |
director, officer: Chief Executive Officer |
C/O MARRONE BIO INNOVATIONS, INC. 1540 DREW AVENUE DAVIS CA 95618 |
| Ardsley Advisory Partners Gp Llc |
other: See Footnotes(1)(2) |
262 HARBOR DRIVE, 4TH FLOOR, STAMFORD CT 06902 |
| Ospraie Management, Llc |
director, 10 percent owner, other: (See Remarks) |
437 MADISON AVENUE, 28TH FLOOR, NEW YORK NY 10022 |
| Ospraie Management, Inc. |
director, 10 percent owner, other: (See Remarks) |
320 PARK AVENUE, 27TH FLOOR, NEW YORK NY 10022 |
| Ospraie Holding I, L.p. |
director, 10 percent owner, other: (See Remarks) |
320 PARK AVENUE, 27TH FLOOR, NEW YORK NY 10022 |
| Dwight Anderson |
director, 10 percent owner, other: (See Remarks) |
C/O OSPRAIE MANAGEMENT, LLC, 320 PARK AVENUE, 27TH FLOOR, NEW YORK NY 10022 |
| Ardsley Healthcare Fund, L.p. |
other: See Footnote (1) |
C/O ARDSLEY PARTNERS I GP, LLC, 262 HARBOR DRIVE, STAMFORD CT 06902 |
| Ospraie Ag Science Llc |
director, 10 percent owner, other: (See Remarks) |
C/O DWIGHT ANDERSON 437 MADISON AVENUE, 28TH FLOOR NEW YORK NY 10022 |
| Van Herk Investments B.v. |
10 percent owner |
LICHTENAUERLAAN 30 ROTTERDAM P7 3062ME |
Marrone Bio Innovations (Marrone Bio Innovations) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MBII has been successfully added to your